192 related articles for article (PubMed ID: 34633840)
1. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
Dekker JG; Klaver B; Berkhout B; Das AT
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
[No Abstract] [Full Text] [Related]
2. Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.
Dekker JG; Klaver B; Berkhout B; Das AT
J Virol; 2024 Jun; 98(6):e0033524. PubMed ID: 38785421
[No Abstract] [Full Text] [Related]
3. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
[TBL] [Abstract][Full Text] [Related]
4. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
5. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).
Ma Q; Schifitto G; Venuto C; Ocque A; Dewhurst S; Morse GD; Aalinkeel R; Schwartz SA; Mahajan SD
J Neuroimmune Pharmacol; 2020 Mar; 15(1):7-9. PubMed ID: 31939069
[No Abstract] [Full Text] [Related]
6. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
7. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir drug-resistance monitoring in Africa.
Kouamou V; Inzaule S; Manasa J
Lancet HIV; 2021 Nov; 8(11):e664-e666. PubMed ID: 34735801
[No Abstract] [Full Text] [Related]
10. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T; Wainberg MA
Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
[No Abstract] [Full Text] [Related]
12. High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy.
Huik K; Hill S; George J; Pau A; Kuriakose S; Lange CM; Dee N; Stoll P; Khan M; Rehman T; Rehm CA; Dewar R; Grossman Z; Maldarelli F
AIDS; 2022 Nov; 36(13):1835-1840. PubMed ID: 35848510
[TBL] [Abstract][Full Text] [Related]
13. Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.
Pham HT; Alves BM; Yoo S; Xiao MA; Leng J; Quashie PK; Soares EA; Routy JP; Soares MA; Mesplède T
J Antimicrob Chemother; 2021 Feb; 76(3):639-647. PubMed ID: 33184634
[TBL] [Abstract][Full Text] [Related]
14. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
15. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
[TBL] [Abstract][Full Text] [Related]
16. High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy.
Duarte FC; Moura LM; Laranjinha J
AIDS; 2022 Nov; 36(13):1881-1882. PubMed ID: 36172870
[No Abstract] [Full Text] [Related]
17. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
[TBL] [Abstract][Full Text] [Related]
18. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
[TBL] [Abstract][Full Text] [Related]
19. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
20. [Resistance profile and genetic barrier of dolutegravir].
Llibre JM; Clotet B
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():20-5. PubMed ID: 25858608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
